Scroll back to the halcyon days of 2020, when the Internet was overflowing with self-love sermons, plus-size runway shows, and pastel infographics reminding us to “embrace every curve.” Now ...

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 months ...

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

A new weight loss treatment that can be taken as either a daily pill or a weekly injection has shown very promising results ...

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.